Additional Gadoxetic Acid Enhanced-MRI for Liver Metastases

Additional Gadoxetic Acid Enhanced-MRI for Liver Metastases - Additional Gadoxetic Acid Enhanced-MRI for Liver Metastases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015024

Enrollment

450

Registered

2014-09-02

Start date

2014-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic liver cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Contrast enhanced CT and gadoxetic acid-enhanced MRI were performed within one month interval. 2. No metastatic hepatic cancer was detected by contrast enhanced CT.

Exclusion criteria

Exclusion criteria: 1. Cases with another malignancy. 2. Contraindication for contrast media, either CT or MRI.

Design outcomes

Primary

Measure	Time frame
Incidence of metastatic hepatic cancer with gadoxetic acid-enhanced MRI with negative result by contrast-enhanced MDCT.	—

Secondary

Measure	Time frame
Imaging characteristics of metastatic hepatic cancer detected by additional gadoxetic acid-enhanced MR	—

Countries

Japan

Contacts

Public ContactTakeyuki Watadani

The University of Tokyo Hospital Department of Radiology

watadat-tky@umin.ac.jp03-5800-8666

Outcome results